|
1
|
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
|
Lancet
|
2007
|
11.27
|
|
2
|
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
|
Arch Gen Psychiatry
|
2006
|
9.44
|
|
3
|
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
|
Am J Psychiatry
|
2003
|
3.18
|
|
4
|
Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia.
|
Schizophr Bull
|
2006
|
2.71
|
|
5
|
The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services.
|
J Clin Psychiatry
|
2015
|
2.67
|
|
6
|
Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.
|
Br J Psychiatry
|
2012
|
2.41
|
|
7
|
Group art therapy as an adjunctive treatment for people with schizophrenia: multicentre pragmatic randomised trial.
|
BMJ
|
2012
|
2.17
|
|
8
|
Effects of cannabis use on outcomes of psychotic disorders: systematic review.
|
Br J Psychiatry
|
2008
|
1.53
|
|
9
|
Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome.
|
Biol Psychiatry
|
2009
|
1.41
|
|
10
|
Abnormal brain connectivity in first-episode psychosis: a diffusion MRI tractography study of the corpus callosum.
|
Neuroimage
|
2006
|
1.20
|
|
11
|
White matter tracts in first-episode psychosis: a DTI tractography study of the uncinate fasciculus.
|
Neuroimage
|
2007
|
1.18
|
|
12
|
Cognitive heterogeneity in first-episode schizophrenia.
|
Br J Psychiatry
|
2005
|
1.11
|
|
13
|
A randomized controlled trial of cognitive-behavior therapy for persistent symptoms in schizophrenia: a five-year follow-up.
|
Schizophr Res
|
2007
|
1.08
|
|
14
|
Role of the prescribing observatory for mental health.
|
Br J Psychiatry
|
2012
|
1.05
|
|
15
|
High-dose and combination antipsychotic prescribing in acute adult wards in the UK: the challenges posed by p.r.n. prescribing.
|
Br J Psychiatry
|
2008
|
1.01
|
|
16
|
The relationship between antisaccades, smooth pursuit, and executive dysfunction in first-episode schizophrenia.
|
Biol Psychiatry
|
2004
|
1.00
|
|
17
|
How to compare doses of different antipsychotics: a systematic review of methods.
|
Schizophr Res
|
2013
|
0.99
|
|
18
|
IQ as a predictor of functional outcome in schizophrenia: a longitudinal, four-year study of first-episode psychosis.
|
Schizophr Res
|
2008
|
0.99
|
|
19
|
The effect of cannabis use and cognitive reserve on age at onset and psychosis outcomes in first-episode schizophrenia.
|
Schizophr Bull
|
2011
|
0.97
|
|
20
|
A window into the brain: an in vivo study of the retina in schizophrenia using optical coherence tomography.
|
Psychiatry Res
|
2012
|
0.96
|
|
21
|
The relationship between IQ, memory, executive function, and processing speed in recent-onset psychosis: 1-year stability and clinical outcome.
|
Schizophr Bull
|
2008
|
0.96
|
|
22
|
No psychiatry without psychopharmacology.
|
Br J Psychiatry
|
2011
|
0.95
|
|
23
|
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
|
J Psychopharmacol
|
2009
|
0.95
|
|
24
|
Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration.
|
Int Clin Psychopharmacol
|
2007
|
0.93
|
|
25
|
Changes in the frontotemporal cortex and cognitive correlates in first-episode psychosis.
|
Biol Psychiatry
|
2010
|
0.92
|
|
26
|
IQ trajectory, cognitive reserve, and clinical outcome following a first episode of psychosis: a 3-year longitudinal study.
|
Schizophr Bull
|
2009
|
0.90
|
|
27
|
Brain pathology in first-episode psychosis: magnetization transfer imaging provides additional information to MRI measurements of volume loss.
|
Neuroimage
|
2009
|
0.90
|
|
28
|
Medicines Reconciliation on Admission to Inpatient Psychiatric Care: Findings from a UK Quality Improvement Programme.
|
Ther Adv Psychopharmacol
|
2011
|
0.89
|
|
29
|
Relationship between insight, cognitive function, social function and symptomatology in schizophrenia: the West London first episode study.
|
Eur Arch Psychiatry Clin Neurosci
|
2006
|
0.87
|
|
30
|
Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia.
|
J Neurosci Res
|
2011
|
0.87
|
|
31
|
Lithium in bipolar and other affective disorders: prescribing practice in the UK.
|
J Psychopharmacol
|
2010
|
0.87
|
|
32
|
Gaze strategies during planning in first-episode psychosis.
|
J Abnorm Psychol
|
2007
|
0.86
|
|
33
|
Schizophrenia--time to commit to policy change.
|
Schizophr Bull
|
2014
|
0.86
|
|
34
|
A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine.
|
Value Health
|
2007
|
0.85
|
|
35
|
Nocturnal enuresis with antipsychotic medication.
|
Br J Psychiatry
|
2012
|
0.85
|
|
36
|
A volumetric MRI and magnetization transfer imaging follow-up study of patients with first-episode schizophrenia.
|
Schizophr Res
|
2006
|
0.84
|
|
37
|
Non-verbal behaviour of patients with schizophrenia in medical consultations--a comparison with depressed patients and association with symptom levels.
|
Psychopathology
|
2010
|
0.84
|
|
38
|
The determinants and effect of shared care on patient outcomes and psychiatric admissions - an inner city primary care cohort study.
|
Soc Psychiatry Psychiatr Epidemiol
|
2004
|
0.84
|
|
39
|
Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia.
|
Schizophr Res
|
2013
|
0.82
|
|
40
|
Structural neural networks subserving oculomotor function in first-episode schizophrenia.
|
Biol Psychiatry
|
2004
|
0.81
|
|
41
|
Monitoring lithium therapy: the impact of a quality improvement programme in the UK.
|
Bipolar Disord
|
2013
|
0.79
|
|
42
|
Informing patients of the teratogenic potential of mood stabilizing drugs: a case note review of the practice of psychiatrists.
|
J Psychopharmacol
|
2007
|
0.79
|
|
43
|
Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used.
|
Br J Psychiatry
|
2010
|
0.78
|
|
44
|
Non-neurological and metabolic side effects in the Cost Utility of the Latest Antipsychotics in Schizophrenia Randomised Controlled Trial (CUtLASS-1).
|
Schizophr Res
|
2013
|
0.77
|
|
45
|
The ANNSERS (Antipsychotic Non-Neurological Side Effects Rating Scale): Validation of Sexual Side-Effect Measurement.
|
Ther Adv Psychopharmacol
|
2011
|
0.76
|
|
46
|
Prescribing and monitoring lithium therapy: summary of a safety report from the National Patient Safety Agency.
|
BMJ
|
2010
|
0.75
|
|
47
|
Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the cutlass study.
|
Int J Psychiatry Clin Pract
|
2005
|
0.75
|